Esperion Therapeutics (ESPR) Tops Q2 EPS by 15c

Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.46), $0.15 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $25.79 million versus the consensus estimate of $24.64 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Barclays Starts Tower Semiconductor (TSEM) at Overweight
• Nucor projects Q3 2026 earnings above prior year, below estimates